Literature DB >> 15262340

Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling.

O Selbach1, N Doreulee, C Bohla, K S Eriksson, O A Sergeeva, W Poelchen, R E Brown, H L Haas.   

Abstract

Orexins (OX), also called hypocretins, are bioactive peptides secreted from glucose-sensitive neurons in the lateral hypothalamus linking appetite, arousal and neuroendocrine-autonomic control. Here, OX-A was found to cause a slow-onset long-term potentiation of synaptic transmission (LTPOX) in the hippocampus of young adult mice. LTPOX was induced at Schaffer collateral-CA1 but not mossy fiber-CA3 synapses, and required transient sharp wave-concurrent population field-burst activity generated by the autoassociative CA3 network. Exogenous long theta-frequency stimulation of Schaffer collateral axons erased LTPOX in intact hippocampal slices but not mini slices devoid of the CA3 region. Pharmacological analysis revealed that LTPOX requires co-activation of ionotropic and metabotropic glutamatergic, GABAergic, as well as noradrenergic and cholinergic receptors. Together these data indicate that OX-A induces a state-dependent metaplasticity in the CA1 region associated with sharp-wave and theta rhythm activity as well as glutamatergic, GABAergic, aminergic, and cholinergic transmission. Thus, orexins not only regulate arousal threshold and body weight but also threshold and weight of synaptic connectivity, providing a molecular prerequisite for homeostatic and behavioral state-dependent control of neuronal plasticity and presumably memory functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262340     DOI: 10.1016/j.neuroscience.2004.05.012

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  25 in total

1.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  Waking with the hypothalamus.

Authors:  Helmut L Haas; Jian-Sheng Lin
Journal:  Pflugers Arch       Date:  2011-07-28       Impact factor: 3.657

4.  Aging-related alterations in orexin/hypocretin modulation of septo-hippocampal amino acid neurotransmission.

Authors:  E M Stanley; J R Fadel
Journal:  Neuroscience       Date:  2011-08-22       Impact factor: 3.590

Review 5.  Food for thought: the role of appetitive peptides in age-related cognitive decline.

Authors:  Jim R Fadel; Corinne G Jolivalt; Lawrence P Reagan
Journal:  Ageing Res Rev       Date:  2013-02-13       Impact factor: 10.895

6.  Aging-related deficits in orexin/hypocretin modulation of the septohippocampal cholinergic system.

Authors:  Emily M Stanley; Jim Fadel
Journal:  Synapse       Date:  2012-02-15       Impact factor: 2.562

7.  Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1).

Authors:  Coleman B Calva; Habiba Fayyaz; Jim R Fadel
Journal:  J Neurochem       Date:  2018-01-12       Impact factor: 5.372

Review 8.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

9.  Phase shift in the 24-hour rhythm of hippocampal EEG spiking activity in a rat model of temporal lobe epilepsy.

Authors:  David A Stanley; Sachin S Talathi; Mansi B Parekh; Daniel J Cordiner; Junli Zhou; Thomas H Mareci; William L Ditto; Paul R Carney
Journal:  J Neurophysiol       Date:  2013-05-15       Impact factor: 2.714

Review 10.  Experience-dependent plasticity in hypocretin/orexin neurones: re-setting arousal threshold.

Authors:  X-B Gao; A H Wang
Journal:  Acta Physiol (Oxf)       Date:  2009-09-24       Impact factor: 6.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.